From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: STX

Search articles by EPIC code

Each morning, I am disappointed by Shield Therapeutics

On February 18, I generated industrial-scale abuse (of me) from anonymous internet warriors. All I did was suggest Shield Therapeutics (STX) as a slam-dunk short, at 25.5p.  The savants insisted, as is usually the case in such circumstances, that I didn’t understand the maths, and should go back to working in a pizza store, etc, etc, etc. The shares are now just 14.6p, and the final collapse is almost upon us. Add to your shorts. Let me explain.


The Shield Therapeutics short – how’s the cash crisis going, fellas – what are your auditors saying?

When I suggested Shield Therapeutics (STX) was a nailed-down short, on the basis that it would face a cash crisis by May, my analysis was met with derision by Bulletin Board Morons. “He does not understand biotech, he does not understand Shield, he’s a failed fund manager, he is ALWAYS wrong, he works in a pizza store, he’s fleeing the UK to Greece to avoid jail”, were some of the more polite comments. It is now May, and the shares are just 17p to sell. So, what next?


BREAKING: Shield Therapeutics IS the next Omega, a short at 25.5p - target 5.5p

Shield Therapeutics (STX) has the status Omega Diagnostics (ODX) once had as a darling of the Bulletin Board savants. And like Omega was this company is heading for a cash crisis and its shares will tank by 80%. Though this will enrage a shareholder base with the collective IQ of a cheese sandwich, the shares are a stand out short at 25.5p with a 5.5p target.  Chaps and gals ,before you start the hate attacks on me learn from the Omega debacle HERE. Now as to why Shield shares will collapse, here’s why.


Company Giving Hope to Millions of Iron Deficiency Sufferers Could Continue its Spectacular Rally

Hello, Share Trappers. You may recall my weekend ramblings when I suggested that supporting some medical pioneers might be worth considering. One reason is that rewards, when they come, are spectacular. Though it must be observed in the same breath that setbacks can be catastrophic. Just like mining shares, the failures seem to come faster than the successes. So anyone who doesn't like too much risk should look away now...

Page 1 of 2 (13 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments